Shares of Akums Drugs surged 4% following a Buy rating by brokerage firm Ambit, with a target price (TP) of Rs 840. The recommendation comes as the company is seen as an attractive alternative play on India’s growing pharmaceutical sector.
Akums Drugs, a leading manufacturer of generic drugs, is strategically positioning itself to scale up its business in new verticals. Ambit highlighted that despite the company’s current earnings weakness, it is expected that its growth will accelerate from FY26 onwards. This temporary slowdown is not a concern, with Ambit projecting a significant ramp-up in performance as Akums leverages its strengths to capitalize on new opportunities.
The brokerage also pointed out that Akums’ valuation is currently at a discount compared to its peers, making it an appealing investment. The pharmaceutical sector in India continues to offer robust growth potential, driven by rising healthcare needs and a strong domestic manufacturing base.
Akums Drugs’ shares opened at ₹613.00, reaching a high of ₹640.05 and a low of ₹613.00 during the trading session. The stock has experienced a 52-week high of ₹1,175.90 and a 52-week low of ₹530.05, indicating significant fluctuations.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
